Certified by Founder
Lodge
Alamar Biosciences, Inc.
start up
United States
- Fremont, California
- 27/02/2024
- Series C
- $128,000,000
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.
- Industry Biotechnology Research
- Website https://alamarbio.com/
- LinkedIn https://www.linkedin.com/company/alamar-biosciences-inc/